State Street Corp Acquires 18,050 Shares of Quanterix Co. (NASDAQ:QTRX)

State Street Corp grew its holdings in shares of Quanterix Co. (NASDAQ:QTRX) by 2.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 836,443 shares of the company’s stock after buying an additional 18,050 shares during the quarter. State Street Corp owned 2.18% of Quanterix worth $10,840,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the business. nVerses Capital LLC purchased a new position in Quanterix during the third quarter worth approximately $60,000. SG Americas Securities LLC purchased a new position in Quanterix during the 3rd quarter worth approximately $139,000. Canada Pension Plan Investment Board acquired a new position in Quanterix in the 2nd quarter valued at about $140,000. Hsbc Holdings PLC raised its stake in shares of Quanterix by 34.7% during the second quarter. Hsbc Holdings PLC now owns 12,738 shares of the company’s stock worth $164,000 after purchasing an additional 3,279 shares during the last quarter. Finally, Intech Investment Management LLC purchased a new stake in shares of Quanterix during the 3rd quarter worth $170,000. Institutional investors own 86.48% of the company’s stock.

Quanterix Stock Performance

Shares of QTRX stock opened at $11.07 on Friday. The stock has a market capitalization of $424.86 million, a price-to-earnings ratio of -10.54 and a beta of 1.30. Quanterix Co. has a one year low of $9.87 and a one year high of $29.70. The company’s 50-day simple moving average is $12.29 and its 200-day simple moving average is $12.95.

Analyst Upgrades and Downgrades

Separately, TD Cowen lifted their price objective on Quanterix from $13.50 to $16.00 and gave the company a “hold” rating in a research report on Wednesday, November 13th.

Quanterix Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.